tested positive; Dizzy; 10 bloody noses; This spontaneous case was reported by a nurse and describes the occurrence of EPISTAXIS (10 bloody noses), COVID-19 (tested positive) and DIZZINESS (Dizzy) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031h21a, 039A21A and 048A21A) for COVID-19 vaccination.     Concurrent medical conditions included Dyslexia (Healthy patient was dyslexic). Concomitant products included NIRMATRELVIR, RITONAVIR (PAXLOVID) from 14-May-2022 to May 2022 for COVID-19 treatment, GUAIFENESIN (MUCINEX) from 14-May-2022 to 15-May-2022, IBUPROFEN (ADVIL [IBUPROFEN]) from 14-May-2022 to 15-May-2022 and AMOXICILLIN from 08-May-2022 to 12-May-2022 for an unknown indication.   On 07-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-May-2022, the patient experienced EPISTAXIS (10 bloody noses) and DIZZINESS (Dizzy). On 19-May-2022, the patient experienced COVID-19 (tested positive). On 16-May-2022, EPISTAXIS (10 bloody noses) and DIZZINESS (Dizzy) had resolved. At the time of the report, COVID-19 (tested positive) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-May-2022, SARS-CoV-2 test: positive (Positive) tested positive on the 5/19 and every day since. On an unknown date, SARS-CoV-2 test: negative (Negative) tested negative for 2 days on 4 test.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient was taking Paxlovid for treatment of COVID-19. No allergies were reported.  Company comment: This spontaneous case concerns a 20-year-old female patient with no relevant medical history, who experienced the unexpected non-serious of Covid-19, approximately five months after receiving the 3rd dose of mRNA-1273 vaccine. The patient received Paxlovid (Nirmatrelvir + Ritonavir) orally for Covid-19. After five days from starting Paxlovid the SARS-CoV-2 test was positive. Details of symptoms, clinical course, further investigation details were not provided. The outcome was reported as unknown. Eight months prior to the 3rd dose, the patient had taken two primary doses of mRNA-1273. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 20-year-old female patient with no relevant medical history, who experienced the unexpected non-serious of Covid-19, approximately five months after receiving the 3rd dose of mRNA-1273 vaccine. The patient received Paxlovid (Nirmatrelvir + Ritonavir) orally for Covid-19. After five days from starting Paxlovid the SARS-CoV-2 test was positive. Details of symptoms, clinical course, further investigation details were not provided. The outcome was reported as unknown. Eight months prior to the 3rd dose, the patient had taken two primary doses of mRNA-1273. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.